display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic glioblastoma (mGB) - 1st line (L1)
metastatic glioblastoma (mGB) - 1st line (L1)
anti-PD-(L)1
nivolumab based treatment
nivolumab alone Checkmate 143

Study type: